---
schema_version: "secwatch.filing_event.v1"
accession: "0001356576-23-000031"
form_type: "8-K"
ticker: "SUPN"
cik: "0001356576"
company_name: "SUPERNUS PHARMACEUTICALS, INC."
filed_at: "2023-05-09T23:59:59+00:00"
generated_at: "2026-06-15T08:35:10.761440+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Supernus Q1 revenue flat at $153.8M; Qelbree sales triple to $25.8M; raises FY 2023 guidance

## Summary
- Q1 total revenues $153.8M (+1% YoY); GAAP operating earnings $5.2M vs $2.0M; net earnings $16.9M ($0.29/sh) vs $25.6M ($0.43/sh).
- Qelbree net sales $25.8M (vs $8.3M YoY); GOCOVRI $26.0M (+15%); Trokendi XR fell 45% to $34.8M due to generic entry.
- Excluding Trokendi XR, net product sales up 25% YoY; total IQVIA Qelbree prescriptions rose 14% QoQ to 134,530.
- Raising FY 2023 GAAP operating loss guidance to $(30)-$(10)M from $(40)-$(10)M; non-GAAP operating earnings raised to $75-100M.
- Repaid $402.5M of 0.625% convertible notes due 2023 on April 1; credit line balance of $78.4M to be fully repaid by Q2 2023.

## SEC filing metadata
- accession: 0001356576-23-000031
- form_type: 8-K
- ticker: SUPN
- cik: 0001356576
- company_name: SUPERNUS PHARMACEUTICALS, INC.
- filed_at: 2023-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1356576/000135657623000031/0001356576-23-000031-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1356576/000135657623000031/supn-20230509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001356576-23-000031
- JSON: https://secwatch.observer/filing/0001356576-23-000031.json
- Plain text: https://secwatch.observer/filing/0001356576-23-000031.txt

## Key facts
- Earnings Releases
  SUPERNUS PHARMACEUTICALS, INC. reported First Quarter 2023 results: revenue 153.8 million, net income 16.9 million, EPS 0.29. Guidance raised.
  - Period: First Quarter 2023
  - Revenue: 153.8 million
  - Net income: 16.9 million
  - EPS: 0.29
  - Guidance: raised
  - Result: reported results
  source text: Supernus Announces First Quarter 2023 Financial Results • First quarter 2023 total revenues of $153.8 million, compared to $152.5 million in first quarter 2022 – Qelbree ® net product sales of $25.8 million, compared to $8.3 million in first quarter 2022 – GOCOVRI ® net product sales of $26.0 million, compared to $22.6 million in first quarter 2022 – Excluding net product sales of Trokendi XR ® in both periods, total net product sales increased 25% • First quarter 2023 GAAP operating earnings of $5.2 million, compared to $2.0 million in first quarter 2022 • First quarter 2023 non-GAAP operating earnings of $30.5 million, compared to $28.0 million in first quarter 2022 • Raises full year 2023 GAAP and non-GAAP operating earnings guidance ROCKVILLE, MD, May 9, 2023 – Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced financial results for
  evidence_url: https://www.sec.gov/Archives/edgar/data/1356576/000135657623000031/0001356576-23-000031-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.